Table 5. Adjusted^f hazard ratios of AMI event (recurrent AMI or CV death) according to coxib and NSAID exposition: results from the conditional logistic regression analyses.

AMI event	Cases	Controls	Crude HR	Adjusted HR (95% CI)
New use
Rofecoxib	20	429	0.91	1.94 (1.32; 2.86)**
Celecoxib	17	383	0.86	1.19 (0.74; 1.93)
NSAID	17	185	1.79	2.28 (1.35; 3.84)*
Past use	947	20587	0.96	0.95 (0.87; 1.03)
No use	3145	61200	1.00	1.00 (reference)
Current use
Rofecoxib	56	1366	0.80	1.36 (1.04; 1.77)*
Celecoxib	61	2138	0.56	0.93 (0.73; 1.19)
NSAID	36	782	0.90	1.39 (0.99; 1.94)
Past use	838	17048	0.96	0.93 (0.85; 1.02)
No use	3155	61450	1.00	1.00 (reference)
Use in last week
Rofecoxib	70	1565	0.87	1.23 (0.95; 1.59)
Celecoxib	88	2418	0.71	1.00 (0.80; 1.26)
NSAID	41	897	0.89	1.28 (0.93; 1.76)
Past use	795	16537	0.94	0.94 (0.86; 1.03)
No use	3152	61367	1.00	1.00 (reference)
Use in last month
Rofecoxib	106	2109	0.98	1.20 (0.96; 1.50)
Celecoxib	120	3006	0.78	0.99 (0.81; 1.21)
NSAID	55	1236	0.87	1.28 (0.98; 1.69)
Past use	720	15233	0.92	0.93 (0.84; 1.02)
No use	3145	61200	1.00	1.00 (reference)

^*p <0.05;

^**p <0.001;

^***p <0.0001;

^fAdjusted for age, gender, time of cohort entry, revascularization and length of stay at index hospitalization, comorbidity index, and exposure to aspirin, beta-blockers, ACE inhibitors and statins; HR, hazard ratios.